Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. Its products in various stages of development include KP-104, a dual-complement inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) which is in Phase 2; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders. The company is headquartered in Redwood City, California.…
Jasper Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants
Jasper Therapeutics (NASDAQ: JSPR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 8.690 USD on 20 November 2026, down 83.7% over 52 weeks. Its 52-week range is 8.470 USD to 72.60 USD: the price is 88.0% below the high and 2.6% above the low.
Its market capitalisation is 9.64M USD.
Jasper Therapeutics reports an operating margin of 0.0%.
Its Piotroski F-score is 0 out of 9, a weak reading of its financial health. The next earnings report is expected on 29 March 2027.